Prostate Cancer | Karim Fizazi, MD, PhD

published 2 months ago by Dr Neil Love

Prostate Cancer Update, Issue 1, 2020 — Part 2: Our interview with Dr Fizazi highlights the following topics as well as cases from his practice: Case: A man in his early 70s with nonmetastatic CRPC receives darolutamide in combination with ADT on the ARAMIS trial (00:00) Effect of PSA doubling time on prognosis of patients with nonmetastatic CRPC (02:40) Results of the Phase III PROSPER, SPARTAN and ARAMIS trials evaluating enzalutamide, apalutamide and darolutamide, respectively, for patients with nonmetastatic CRPC (04:50) Tolerability of enzalutamide, apalutamide and darolutamide (08:49) Activity and side-effect profile of darolutamide for nonmetastatic CRPC (15:47) Approaches to preventing bone loss in men receiving ADT (19:03) Optimal integration of radium-223 into current mCRPC treatment algorithms (20:55) Efficacy and safety with the combination of radium-223 and abiraterone or enzalutamide for mCRPC (23:20) Selection and sequencing of therapy for patients with mCRPC; role of enzalutamide for patients who experience disease relapse on abiraterone and vice versa (26:12) Results of the CARD study: Cabazitaxel versus enzalutamide or abiraterone for patients with mCRPC previously treated with docetaxel who experienced rapid disease progression on a prior androgen receptor-targeted agent (28:47) Role of AR-V7 in clinical decision-making for patients with disease progression on secondary hormonal therapy (30:39) Diagnosis and incidence of metastasis in men presenting with HSPC (33:18) STAMPEDE: Radiation therapy to the primary tumor improves survival for the subgroup of patients with newly diagnosed mPC and low metastatic burden (37:18) Efficacy of chemotherapy or secondary hormonal therapy in combination with ADT for patients with mHSPC (40:25) Activity of antiandrogens for patients with PC (43:55) Role of taxanes in the management of PC; comparison of the efficacy and tolerability of cabazitaxel versus docetaxel (46:50) Germline and somatic testing for patients with mPC (51:44) Case: A man in his late 70s with mCRPC and a germline BRCA2 mutation achieves a good response to a PARP inhibitor on a clinical trial (53:45) Efficacy and tolerability of olaparib, rucaparib and niraparib in patients with mPC (59:16) Activity of platinum-based chemotherapy for patients with mPC and BRCA mutations (1:03:44) Potential benefit of PARP inhibitors in patients with PC and alternative DNA damage repair alterations (eg, ATM, CDK12); results from the PROfound trial (1:06:32) CME information and select publications

more episodes from Research To Practice | Oncology Videos